Improving safety checks for new eczema (atopic dermatitis) medicines in real-world patients
Official title: New approaches to safety monitoring of novel systemic treatments for atopic dermatitis in clinical practice and underrepresented populations
Funded at Brigham and Women's Hospital · NIH-11289419 · Data updated 2026-11-12
This work looks for safety problems with new immune-targeting eczema medicines using health records from millions of Americans, including children, pregnant-age women, and other groups often left out of clinical trials.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | February 1, 2022 |
| Project end | December 31, 2026 |
| Funding year | 2026 |
| Award (this year) | $570,768 |
| NIH project number | 5R01AR080194-05 |
| Project ID | NIH-11289419 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with severe or treatment-resistant atopic dermatitis who are using or considering systemic immunomodulator medicines, including children and those with multiple health problems, are the main focus.
✕Less likely to help
People with mild eczema who are not on systemic therapies or anyone whose medical care is not captured in U.S. insurance or electronic health record databases are less likely to benefit directly.
What this research studies
The team will analyze linked electronic health records and insurance claims covering over 78 million Americans to detect side effects of new systemic immunomodulator drugs for severe atopic dermatitis. They will use advanced causal inference methods to reduce bias and produce more reliable safety estimates that reflect everyday clinical care. The project deliberately includes populations typically excluded from trials, such as children, reproductive-age women, Medicaid beneficiaries, and people with complex health conditions. Results are intended to speed detection of safety signals and support more personalized treatment choices.
Why it matters
Potential benefit: Could help patients and clinicians choose safer eczema treatments by revealing rare or subgroup-specific side effects more quickly.
How similar studies have gone: Large pharmacoepidemiology and safety-monitoring efforts have successfully identified drug risks before, and this project applies those established methods to new eczema drugs and underserved groups.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Schneeweiss, Sebastian G. — Brigham and Women's Hospital
- Study coordinator: Schneeweiss, Sebastian G.
Related research
Other NIH-funded projects on the same topics.
-
Stopping Atopic Dermatitis and Allergy: Preventing Food Allergy by Protecting the Skin
A large study in infants at high risk for allergies tests whether using a skin barrier cream together with early, proactive skin care can prevent peanut allergy and other food allergies.
-
SEAL Study: Preventing peanut allergy by protecting baby skin
This trial tests whether using a skin-emollient and proactive skin steroids early in life can prevent peanut allergy in high-risk infants.
-
SEAL Study: Prevent allergy by protecting the baby’s skin
A very young group of high-risk babies will try a early skin-care plan to reduce eczema and prevent peanut allergy.
-
Understanding how skin fungi affect atopic dermatitis in adults
A study will look at how the skin's fungal community influences atopic dermatitis in adults and whether this understanding could lead to new treatments.
-
Preventing eczema-related allergies by strengthening infants' skin barrier
This project will see if using a trilipid skin cream plus proactive mild topical steroids in infants with early dry skin or eczema lowers their chances of developing food allergies.
-
Personalized predictions for how atopic dermatitis may progress in kids and teens
A patient-friendly plan to forecast how early-onset eczema might evolve in children and young people using simple health clues and data from diverse settings.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.